Drug Trial Radar · NCT03514511
Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
May 7, 2018
Primary completion
Mar 2, 2021
Study completion Mar 2, 2021
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis. The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of LEO 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis. Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen per subject). Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of LEO 138559 (one dose regimen per subject).
Conditions
- Atopic Dermatitis
Interventions
LEO 138559Drug
LEO 138559 is a compound in development at LEO Pharma A/S
LEO 138559 placeboDrug
LEO 138559 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of LEO 138559 - numbers of subjects with adverse eventsTime frame: Day 1 to Day 120
- Safety of LEO 138559 - number of adverse eventsTime frame: Day 1 to Day 120
- Tolerability of LEO 138559 - number of local site reactionsTime frame: Day 1 to Day 120
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigational site
Leeds, United Kingdom
Investigational site
Liverpool, United Kingdom
LEO Pharma investigational site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.